HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
User noticed tiny dots on their head after using 0.5% dutasteride and 8% minoxidil, which others identified as developing hair follicles. Encouragement was given to continue the treatment.
Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.